Intera Atlas
Run match
Sites / Pinnacle Clinical Research
Is this you?

Request access for Pinnacle Clinical Research with your @pinnacleresearch.com work email. Intera will contact you to verify and set up your account — nothing auto-publishes.

Request account

Pinnacle Clinical Research

Unclaimed profile

SMO · San Antonio, TX · ~12+ sites

WebsiteLinkedInRank for protocol
Intera lens
ICP 8Lift (cardio sample) 0.06Recruit soph 0.86
Quality Scorecard (1–100)
Overall86Recruit83Ops87Sponsor90Ther84

Performance (observed)

Historical trials
423
Completed
255
Terminated/Withdrawn
41
Completion rate
86%
Active now
123
Phase 2
144
Phase 3
181
Realized enrollment
442,173
First study year
1998
Years active
28
Match confidence
high
Enrollment velocity (inf)
15,792

Therapeutic

Areas
Hepatology (liver disease, NAFLD, NASH focus), Gastroenterology, CNS (Alzheimer's Disease), Metabolic Disorders, Cardiovascular
Specialties
CNS, Obesity, Liver Disease (MASLD/MASH), Alzheimer's
Breadth (conditions)
564
Languages
English + Spanish (detected)
States
TX (multiple: San Antonio, Austin, Georgetown, Dallas, Houston, Brownsville, Corpus Christi, Edinburg), NJ (Ridgewood, Springfield), NV (Las Vegas)

Recruitment (web observed)

Meta Pixel
Yes
Facebook Ads
Yes
Google Ads
Yes
Patient database
Y
Recruitment pages
Yes
Advertises recruitment
Yes
SEO
Y
Capability notes
Fast, reliable recruitment; diverse population access; experience with complex trials; rapid enrollment timelines

Relationships

Sponsors
National Cancer Institute (NCI); Eli Lilly and Company; Pfizer; Gilead Sciences; Hoffmann-La Roche; Boehringer Ingelheim
CROs
IQVIA Pty Ltd; MacroGenics; Medpace, Inc.; PPD Development, LP; PRA Health Sciences; Parexel
Partnerships
Network of member clinics
Owner / parent
LongueVue Capital (PE-backed, Nov 2022); founder Dr. Stephen Harrison (passed April 2024); CEO Adrian Otte (35+ yrs pharma/life sciences experience at Amgen, Pfizer, PAREXEL)
Funding
PE - LongueVue Capital (November 2022)
Acquisitions
Kerwin Medical Center, The Cognitive and Research Center of NJ, Bellaire Clinical Research, Palmetto Low Country, Dallas Research Institute, South Texas Research Institute
Expansion
Y - 12 sites (2024), acquired Kerwin, CRCNJ, Bellaire, Palmetto Low Country, Dallas Research Institute
Recent hiring
Y - rapid expansion with acquisitions

Capacity & people

Investigators
—
Coordinators
—
CEO
Adrian Otte
VP Clinical Ops
Unknown
VP Site Ops
Unknown
VP Recruitment
Unknown
Emails
info@pinnacleresearch.com; peopleandculture@pinnacleresearch.com

Tech & DCT

eSource
Yes
Builds tech
Unknown
DCT / decentralized
Y - 15 sites across 3 states (TX, NJ) and expanding
Tech stack
Unknown
Recruiting visible
Y

Notes

PE-backed multi-site network; 12+ sites as of 2024 (rapid expansion from 3 in 2022); specialized expertise in complex therapeutic areas (hepatology, liver disease); diversified therapeutic portfolio post-acquisitions; multiple concurrent recruiting studies; strong enrollment track record. Growth-focused platform. Good Intera fit: scale, recruitment focus, multiple studies, PE-backed momentum. [Validated: 12 active recruiting cardiometabolic trials on ClinicalTrials.gov.]

Recommendation features (sample indication)

Ind fit 0.42Liftability 0.06Overall86

FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.